Hmgb1 antagonist treatment of acute lung injury

Patent metadata

Field	Value
Publication number	US-2020354418-A1
Application number	US-202016869913-A
Country	US
Kind code	A1
Filing date	May 8, 2020
Priority date	May 9, 2019
Publication date	Nov 12, 2020
Grant date	—

First claim

What is claimed is:

1 . A method of treating and/or inhibiting acute lung injury in a mammal comprising administering to a mammal a therapeutically effective amount of a peptidomimetic small molecule modeled after an HMGB1 antagonist tetramer peptide.

2 . The method of claim 1 , wherein the peptidomimetic small molecule is an HMGB1 antagonist tetramer peptide which has been stabilized with at least one azatide linkage.

3 . The method of claim 2 , wherein the peptidomimetic small molecule is a modified P5779 wherein at least one terminal peptide bond has been replaced with an azatide linkage.

4 . The method of claim 2 , wherein the peptidomimetic small molecule is a modified P5779 wherein the terminal peptide bonds have been replaced with azatide linkages.

5 . The method of claim 2 , wherein the peptidomimetic small molecule is K883.

6 . The method of claim 1 , wherein the mammal is a human.

7 . The method of claim 1 , wherein the therapeutically effective amount is orally administered to the mammal.

8 . The method of claim 1 , wherein the therapeutically effective amount is intravenously administered to the mammal.

9 . The method of claim 7 , wherein the mammal is human.

10 . The method of claim 8 , wherein the mammal is human.

11 . A method of treating and/or inhibiting the effects of COVID-19 or other SARS viruses in a mammal comprising administering to a mammal a therapeutically effective amount of a peptidomimetic small molecule modeled after an HMGB1 antagonist tetramer peptide.

12 . The method of claim 11 , wherein the peptidomimetic small molecule is an HMGB1 antagonist tetramer peptide which has been stabilized with at least one azatide linkage.

13 . The method of claim 12 , wherein the peptidomimetic small molecule is a modified P5779 wherein at least one terminal peptide bond has been replaced with an azatide linkage.

14 . The method of claim 12 , wherein the peptidomimetic small molecule peptidomimetic small molecule is a modified P5779 wherein the terminal peptide bonds have been replaced with azatide linkages.

15 . The method of claim 11 , wherein the peptidomimetic small molecule is K883.

16 . The method of claim 1 , wherein the method of administration is selected from the group consisting of oral delivery, parenteral delivery, buccal delivery, sublingual delivery, nasal delivery, inhalation delivery, nebulization delivery, topical delivery, transdermal delivery and suppository delivery.

17 . The method of claim 4 , wherein the K883 is combined with an excipient comprising PBS:PEG 300:propylene glycol:polysorbate 80 at 50:40:5:5.

18 . A method of treatment of acute lung injury, comprising identifying a human patient exhibiting symptoms of acute lung injury, and administering a modified P5779 with at least one azatide linkage.

19 . The method of claim 19 , wherein the modified P5779 has at least one azatide linkage located at a terminal peptide bond.

20 . The method of claim 20 , wherein the modified P5779 is K883.

Assignees

• Feinstein Institutes For Medical Research

Inventors

• Al-Abed Yousef

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K5/1016

  and aromatic or cycloaliphatic · CPC title

• C07K5/06069

  Ser-amino acid · CPC title

• C07K1/113

  without change of the primary structure · CPC title

• A61P25/02 Primary

  for peripheral neuropathies · CPC title